510(k) clearance of Densitas’ advanced machine learning algorithm empowers radiologists with on-demand actionable information at point-of-care
VIENNA, Austria – March 1 2018 – Breast imaging analytics innovator Densitas Inc. announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its machine learning breast density assessment software. The software empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions. “Receiving 510(k) clearance marks a significant milestone in our company’s growth as we expand our global reach into the U.S. market with our flagship product,” said Mohamed Abdolell, CEO of Densitas. We are delighted to be entering the largest medical device market in the world, especially as 31 states have passed mandatory breast density notification laws.” Breast density has been shown to be strongly associated with cancer risk. Densitas has the distinct advantage of facilitating breast density assessments of routinely stored standard processed images and their priors because the technology processes the same standard digital mammograms that radiologists view. This provides a practical solution for integrating breast density into risk-based models in population-based screening. The software is cleared for clinical use in the U.S., Europe, Canada and Australia, and is the first of several follow-on products. The software is being showcased at the European Congress of Radiology (ECR 2018), booth 114 at the Austria Center Vienna. About Densitas Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs. For more information, visit www.densitas.health. Contact Alex Morris [email protected] Mobile: 1-647- 470-4363]]>BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Recent Posts
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
Business Wire National BioTech News
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
- Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
- Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
- VHA Introduces Groundbreaking Pontosense AI Solution, Offering New Innovations for Aging in Place
- ZYUS Announces Anticipated Delay in Its Annual Filings
RECENT NEWS
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova February 9, 2023
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
RECENT TWEETS
Notice: Trying to get property 'full_text' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 206
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'id_str' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'favorite_count' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1064
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
Notice: Trying to get property 'name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
·
@
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579